Product Description

Docetaxel is a microtubule depolymerization inhibitor. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity.

Screeningbio‘s K562/Docetaxel resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Docetaxel (Taxotere) is a semisynthetic taxane chemotherapeutic agent that promotes microtubule polymerization and inhibits mitotic spindle disassembly, resulting in cell cycle arrest and apoptosis in rapidly dividing cancer cells. However, the emergence of drug resistance remains a major obstacle limiting its long-term efficacy in various malignancies, including breast, prostate, non-small cell lung, and gastric carcinomas.

Mechanistically, docetaxel resistance arises through multiple cellular adaptations.

Mutations or altered expression of β-tubulin isotypes (particularly class III β-tubulin, TUBB3) reduce drug–microtubule binding affinity, while upregulation of efflux transporters such as P-glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK/ERK, and NF-κB signaling—promotes anti-apoptotic responses. Changes in microtubule-associated proteins (MAPs, e.g., tau, MAP4) and enhanced autophagy or epithelial–mesenchymal transition (EMT) also contribute to reduced drug sensitivity. Unlike paclitaxel, docetaxel shows higher intracellular retention and slower efflux, yet resistance often involves additional factors such as altered tubulin dynamics and cross-resistance to other taxanes.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux inhibitors (e.g., verapamil, elacridar), targeting tubulin isotype expression via siRNA or small molecules, modulating survival signaling (PI3K/mTOR inhibitors), or employing patient-derived resistant cell models to guide personalized therapy development.